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1. Introduction 
Acute kidney injury (AKI) is characterized by a rapid decline in kidney function within a 
few hours or a few days. AKI is an independent risk factor for mortality in critically ill 
patients. Determination of the prevalence of AKI depends on the definition employed and 
on methods used for definite diagnosis. The incidence and prevalence of AKI vary with the 
clinical setting, based on separately addressed community-based, hospital-based or 
intensive care unit (ICU)-based AKI [Himmelfaub, Ikizler 2007].  The epidemiology of AKI 
has been made unclear in the past because of the use of different definitions across various 
studies. The lack of a uniform definition may results in many differences in the reported 
incidences and outcomes of AKI in the literature.  
2. Definition of AKI 
2.1 RIFLE criteria 
In 2004, a group of experts on acute renal failure (Acute Dialysis Initiative, ADQI) stated that 
the name should be changed from ‘‘acute renal failure’’ to ‘‘acute kidney injury (AKI)’’ 
[Bellomo, Ronco, Kellum et al. 2004]. This group developed criteria for standardizing and 
staging AKI, which consist of Risk, Injury, Loss and End-stage Renal Failure (RIFLE). The aim 
of this classification was to standardize the definition of AKI in the same way as the two other 
common ICU syndromes (sepsis and ARDS). In the RIFLE criteria, serum creatinine and urine 
output were adopted as clinical parameters to formulate three severity categories (Risk, Injury 
and Renal Failure) of AKI and two clinical outcome categories (Loss and Renal Failure) (Table 
1). At present, RIFLE criteria have been validated in more than 550,000 patients around the 
world [Srisawat, Hoste, Kellum et al. 2010]. The problems in adopting the criteria were using 
1) very small alterations in serum creatinine and urine output, 2) an acronym instead of 
numerical stages such as with chronic kidney disease (CKD) and 3) a 50% increase of serum 
creatinine for categorizing as Risk. Recent investigations revealed that an alteration of less than 
50% of serum creatinine was important [Chertow, Burdick, Honour 2005]. 
2.2 AKIN criteria 
In 2007, the RIFLE criteria were revised by members of the Acute Kidney Injury Network 
(AKIN), a multi-disciplinary international group to increase their sensitivity [Mehta, 
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Kellum, Shah et al. 2007]. These modifications are summarized as follows: 1) broadening of 
the ‘risk’ category of RIFLE to include an increase in serum creatinine of at least 0.3mg/dL 
even it this does not reach the 50% of the basal creatinine level; 2) setting a 48-hour window 
on the first documentation of any criteria; 3) categorizing all patients as ‘failure’ if they are 
undergoing renal replacement therapy (RRT) regardless of what their serum creatinine or 
urine output is at the point of initiation and 4) using stages 1, 2 and 3 were used instead of 
R, I and F (Table 1). 
3. Etiology of AKI in patients with neoplasms 
The etiology of AKIs is classified into three types: pre-renal, intrinsic renal injury and post-
renal causes [Denker, Robles-Osorio, Sabath 2011]. AKI in patients with neoplasms is most 
often multifactorial. Clinicians may experience each type or combinations of AKI during 
treatment of these patients. 
3.1 Pre-renal causes 
Pre-renal causes are common in patients with malignancies because these patients suffer 
from anorexia, nausea and vomiting or diarrhea as malignancy-related symptoms together 
with side effects of treatments. It is often difficult to diagnose in the pre-renal phase during 
which recovery of kidney function is possible with adequate fluid supplementation and also 
difficult to differentiate from the intrinsic renal renal phase during which AKI has been 
established [Lameire, Van Biesen, Vanholder 2010]. Moreover, electrolyte disturbances are 
frequently observed in patients with malignancies and they can aggravate AKI. Electrolyte 
and acid base disturbances are consequences of neoplastic spread, anticancer treatment or 
paraneoplastic phenomena of tumors.  
3.2 Intrinsic renal causes 
Most intrinsic renal injury is classified as acute tubular necrosis (ATN), acute interstitial 
nephritis, vasculopathy and glomerulopathy.  
3.2.1 Acute tubular necrosis (ATN) 
ATN is defined by AKI and tubular damage in the absence of significant glomerular  
or vascular pathology [John, Herzenberg 2009]. The presentation of ATN is a sudden rise  
of serum creatinine, sometimes with microscopic hematuria and small amounts of 
proteinuria. The presence of tubular epithelial enzymes in the urine is a valuable indicator 
of detect damage. Microscopically, ATN is recognized by a combination of degenerative 
tubular changes. The mildest change is apical blebbing and the most severe is cellular 
necrosis, which is rare. The presence of sloughed epithelium and casts is a common finding. 
Mild interstitial inflammatory cell infiltration is commonly observed around the damaged 
tubular segments. Tamm-Horsfall mucoprotein can elicit an exuberant inflammatory 
reaction. Isometric vacuolization is a form of tubular injury characterized by numerous 
small vacuoles filling the cytoplasm. The pathogenetic mechanism of ATN is still unclear. 
The two major causes of ATN are ischemic and toxic factors. Both lead to ATN via tubular 
epithelial cell damage. Prolonged renal ischemia is the most common cause of ATN. While 
sepsis, commonly observed in critically ill patients with malignancy, is a cause of 
hypotension and renal ischemia, a recent investigation using sepsis models suggested that 
reactions between Gram-negative toxins and toll-like receptors including their effector  
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Table 1. RIFLE and AKIN criteria 
Patients requiring RRT are automatically classified as Stage 3 AKIN regardless of stage at 
time of RRT initiation. 
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proteins such as MyD88 were also involved in ATN [Goncalves, Zamboni , Camara 2010, Li, 
Khan, Maderdrut et al. 2010].   
3.2.2 Tubulointerstitial nephritis 
Tubulointerstitial nephritis is defined as inflammation of the renal interstitium and tubules 
either with interstitial edema and acute tubular damage or with interstitial fibrosis and tubular 
atrophy. Acute interstitial nephritis (AIN) is clinically similar to ATN. Signs suggesting 
systemic hypersensitivity such as rash or eosinophilia are sometimes present. The major causes 
of AIN include drugs, infection, autoimmune diseases and cancer infiltration. The most 
frequent cause is drugs, which account for two thirds of all AIN [Baker, Pusey2004].  The onset 
of symptom after administration of a drug that can induce AIN is on average 2-3 weeks, but 
this interval varies widely [Rossert 2000]. While eosinophilia has been suggested to predict 
drug-induced AIN, good evidence is lacking for diagnosis of AIN based on the presence or 
absence of eosinophilia [Nolan, Anger, Kelleher 1986]. AIN shows interstitial edema, tubular 
damage and mixed infiltration of mononuclear cells. Eosinophilic infiltration is common drug-
induced AIN, but it shows low sensitivity. An immunological basis for drug-induced AIN is 
apparent in most cases. Drugs act as haptens and create antigenicity after binding to tubular 
basement membrane or interstitial matrices [Rossert 2000]. 
3.2.3 Thrombotic microangiopathy 
The association between thrombotic microangiopathy (TMA) and cancer was first described in 
1973. TMA may be associated with cancer itself, with cancer chemotherapy or with allogenic 
bone marrow transplantation (BMT) [Kwaan, Gordon 2001]. Thrombocytopenia with 
microangiopathic hemolytic anemia (peripheral non-autoimmune anemia with schizocytes) 
and no alternative diagnosis is sufficient to establish a presumptive diagnosis of TMA 
[Darmon, Ciroldi, Thiery et al. 2006]. Intravascular coagulation (DIC) must be ruled out in this 
setting. Most TMA occurs in patients with solid tumors, the most common type being 
adenocarcinoma (stomach, breast and lungs) although TMA has been reported in patients with 
other solid tumors or hematological malignancies [Gordon, Kwaan 1997]. While the 
pathophysiology of malignancy-related TMA remains controversial, recent studies have 
shown that disseminated cancer is associated with decreased ADAMTS 13 activity, without 
anti-ADAMTS 13 antibodies [Oleksowicz, Bhagwati, DeLeon-Fernandez 1999]. 
The link between TMA and cancer chemotherapy was first described for mitomycin C. 
Subsequently, TMA has been reported in connection with many anti-cancer agents, including 
gemcitabine, bleomycin, cisplatin, cytosine arabinoside, daunorbicin, deoxycoformycin, 5-FU, 
azathioprine and interferon α[Kwaan, Gordon 2001]. The association between TMA and bone 
marrow transplantation (BMT) has been reported since the 1980s. Typically, TMA starts from 2 
to 12 months after BMT and is unresponsive to plasma exchange. BMT associated TMA has 
been reported to be related to total body irradiation, graft-vs-host disease and cytomegalovirus 
infection. Treatment of TMA has not been established. Although plasma exchange has been 
shown to improve patients without malignancies [Rock, Shumak, Buskard et al. 1991], it is 
possible that plasmatherapy harms TMA patients with malignancies [Penne, Vignau, Auburtin 
et al. 2005].  
3.3 Toxicity related to cancer treatment 
3.3.1 Contrast-induced AKI (CI-AKI) 
CI-AKI accounts for approximately 10% of all cases of hospital-acquired AKI. CI-AKI may 
lead to increased morbidity and mortality rates in the selected at-risk population including 
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critically ill patients with cancer [Briguori, Tavano, Colombo2003]. Hemodynamic changes 
in renal blood flow, which lead to hypoxia of the renal medulla and direct toxic effects of 
contrast media on renal cells are thought to contribute to the pathogenesis of CI-AKI 
[Briguori, Quintavalle, De Micco et al. 2011]. 
3.3.2 Cisplatin-induced renal toxicity 
Metastatic renal pelvic cancers, like those of the bladder, are generally highly 
chemosensitive diseases. At present, a combination of cisplatin, methotrexate, doxorubicin 
and vincristine (M-VAC) is most widely used for the treatment of metastatic urothelial 
carcinoma [Sternberg, Yagoda, Scher et al. 1989, Tannock, Gospodarowicz, Connolly. 1989]. 
The dismal results obtained with M-VAC have prompted efforts to determine new regimens 
against urothelial carcinoma. Combined chemotherapy with gemcitabine and cisplatin is 
now widely considered to be first-line chemotherapy against metastatic renal pelvic cancer 
[von der Maase, Hansen, Roberts et al. 2000, Tanji, Ozawa, Miura et al. 2010].  
Cisplatin has direct toxicity and causes AKI. Cisplatin is also associated with chronic dose-
dependent reduction of the glomerular filtration rate (GFR) [Arany, Safirstein 2003]. The 
most widely used protective measurement is saline infusion to induce solute diuresis. Since 
amifostine (an inorganic thiophosphate) has been found to be effective for prevention of 
AKI, the American Society of Clinical Oncology recommended use of amifostine for the 
prevention of AKI in patients receiving cisplatin-based chemotherapy (grade A 
recommendation) [Schuchter, Hensley, Meropol et al. 2002]. 
Metastatic renal cell carcinoma (RCC) is highly resistant to both conventional chemotherapy 
and radiotherapy. During the last decade, several new targeted drugs (sorafenib, sunitinib, 
everolimus and temsirolimus) have been used for the treatment of advanced RCC [Tanji, 
Yokoyama 2011]. Molecular targeted drugs are associated with adverse events different from 
those of classical anticancer agents. AKI has been reported in patients with advanced RCC 
administered anti-vascular endothelial growth factor (VEGF) agents, including sorafenib and 
sunitinib. Proteinuria and hypertension are often observed in the patients treated with these 
agents and pathologically, various kidney lesions, including thrombotic microangiopathy, 
focal segmental glomerulosclerosis, mesangial proliferative glomerulonephritis, 
cyroglobulinemic glomerulonephritis, immune complex glomerulonephritis, glomerular 
endotheliosis and AIN, are detected [Gurevich, Parazella 2009]. A patient contracting AKI after 
using temsirolimus has been reported [Kwitkowski, Prowell, Ibrahim 2010].  
3.4 Intra- or extra-renal obstruction 
3.4.1 Acute tumor lysis syndrome 
Tumor lysis syndrome (TLS) is a potentially life-threatening complication of cancer 
treatments in patients with extensive growing and chemosensitive malignancies. TLS results 
from degenerated cells, which rapidly release intracellular electrolytes, proteins and 
metabolites into the extracellular space. TLS often causes AKI by renal tubular occlusion 
resulting from uric acid crystal formation secondary to hyperuricemia [Jasek, Day 1994]. 
Another cause is calcium phosphate deposition by hyperphosphatemia [Darmon, Ciroldi, 
Thiery et al. 2006]. Although TLS typically occurs in patients with hematological 
malignancies, it has been reported in patients with RCC and pelvic cancer [Lin, Lim , Chen 
2007, Persons, Garst, Vollmer et al. 1998]. Volume expansion and recombinant urate oxidase 
(rasburicase), which reduce uric acid levels, diminish the risk of uric acid deposition 
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nephropathy. Urine alkalization, which was previously recommended to prevent uric acid 
precipitation within renal tubules, is controversial since urine alkalization induces calcium 
phosphate deposition [Baeksgaard, Sorensen 2003]. 
3.5 Post-renal causes 
Post-renal causes of AKI are based on obstruction of the outflow tracts of the kidneys. 
Causes include prostatic hypertrophy, catheters, tumors, strictures and crystals. Neurogenic 
bladder also causes an obstruction. Clinical manifestations of post-renal obstructive 
uropathy vary with the site, degree and rapidity of obstruction [Kapoor, Chan 2001]. 
B-mode ultrasonography is a very useful imaging tool to rule out the possibly of urinary 
tract obstruction as a cause of AKI [Kalantarinia 2009]. Early detection of urinary tract 
obstruction may prevent patients from progressing to established AKI by early release of 
urinary obstruction [Choudhury 2010]. 
Release of obstruction, either by percutaneous nephrostomy or through a ureteral stent, is 
the fundamental treatment. Recovery of renal function depends on the severity and 
duration of the obstruction [Kapoor and Chan 2001]. Thus, early discovery and treatment 
are crucial. 
4. Biomarkers of AKI 
Although serum creatinine and blood urea nitrogen have been used as standard biomarkers, 
they are not sufficiently specific and sensitive to detect AKI in the early phase [Choudhury 
2010]. Moreover, the resultant inability to meaningfully segregate critical aspects of injury 
such as type, onset, propagation and recovery from ongoing renal function has hindered 
successful translation of promising therapeutics. Recently, efforts to identify novel plasma 
or urine biomarkers for AKI have resulted in discovery about 20 potential candidates. 
Promising markers include urine or plasma neutrophil gelatinase-associated lipocalin 
(NGAL), kidney injury molecule-1 (KIM-1), IL-18, cystatin C and liver fatty-acid binding 
protein (L-FABP) [Malyszko 2010]. 
4.1 NGAL 
Human NGAL is a 25-kDa protein expressed by neutrophils and various epithelial cells 
including cells of the proximal convoluted tubules [Goetz, Holmes, Borregaad et al. 2002]. 
Urinary NGAL is up-regulated within 2 hours after acute renal cellular injury. Microarray 
analysis identified NGAL as one of the earliest and most prominently induced genes in the 
kidneys after ischemic or nephrotoxic renal injury in mouse models and humans [Schmidt-
Ott, Mori, Kalandadze 2006, Cowland, Borregaad 1997]. In one study, patients in an 
intensive care unit with AKI had more than 10-fold increases in plasma NGAL and more 
than 100-fold increases in urine NGAL levels, when compared with controls [Mori, Lee, 
Rapoport et al. 2005]. Other studies demonstrated the ability of serum and/or urine NGAL 
to predict the development of postsurgical AKI before elevation of serum creatinine 
[Mishra, Dent, Tarabishi et al. 2005, Dent, Ma, Dastrala et al. 2007]. 
4.2 KIM-1 
Kidney injury molecule-1 (KIM-1) is a transmembrane protein overexpressed in proximal 
tubule cells of the kidneys in response to ischemic or nephrotoxic injury and has a 
www.intechopen.com
 
Acute Kidney Injury (AKI) and Management of Renal Tumors 
 
189 
potential role as a predictive marker of AKI [Ichimura, Bonventre, Bailly et al. 1998]. In a 
cross-sectional study, the area under the curve (AUC) of KIM-1 for differentiating patients 
with AKI from controls was 0.9 [Han, Waikar, Johnson et al. 2008]. A prospective study  
of 90 adult patients undergoing cardiac surgery indicated that the AUC of urinary  
KIM-1 was higher than those of NGAL and NAG. Several studies demonstrated that 
urinary KIM-1 can differentiate ischemic AKI from pre-renal azotemia and CKD and  
may be useful for differentiating among various subtypes of AKI [Han, Waikar, Johnson 
2008]. 
4.3 Cystatin C  
Cystatin C is a low molecular weight cysteine protease inhibitor. The serum level of cystatin 
C is determined by the glomerular filtration rate (GFR), indicating that serum and urine 
levels of cystatin C reflect changes in the GFR [Villa, Jimenez, Soriano et al. 2005]. Although 
serum creatinine levels do not rise until GFR drops to under 50 ml/min (creatinine blind 
area), serum cystatin C increases at a GFR of around 70ml/min [Shimizu-Tokiwa, Kobata, Io 
et al. 2002]. This means that serum cystatin C is superior to serum creatinine in detecting 
impaired GFR. 
4.4 IL-18 
IL-18 is a proinflammatory cytokine and powerful mediator of ischemia induced AKI  
in animal models [Melnikov, Ecder, Fantuzzi et al. 2001]. Il-18 is induced and cleaved in 
the proximal tubules and is detected in urine following experimental AKI [Melnikov, 
Faubel, Siggmund et al. 2002]. In a cross-sectional study, IL-18 levels were significantly 
higher in patients with established AKI but not in those with urinary tract infections. The 
AUC for diagnosis of established AKI is 0.95 [Parikh, Jani, Melnikov et al. 2004]. In 
general, it is considered that IL-18 is specific for ischemic AKI but may also be a non-
specific marker of inflammation and has shown inconsistent results [Moore, Bellomo, 
Nichol 2010]. 
4.5 L-FABP 
L-FABP is expressed in various organs including the liver and kidneys. The function of L-
FABP is cellular uptake of fatty acids from plasma and promotion of intracellular fatty acid 
metabolism. Since free fatty acids can be easily oxidized, they can lead to oxidative stress 
and cellular injury. L-FABP inhibits the accumulation of intracellular fatty acids and 
prevents oxidation of free fatty acids. L-FABP is an important cellular antioxidant during 
oxidative stress [Noiri, Doi, Negishi et al. 2009]. 
L-FABP is filtered by glomeruli and reabsorbed in the proximal tubules. This partly explains 
the increase of L-FABP in injury of the proximal tubules. Renal L-FABP expression is up-
regulated and urinary L-FABP excretion is accelerated by accumulation of free fatty acids in 
proximal tubule injury [Kamijo, Sugaya, Hikawa et al. 2004, ]. 
In a clinical study, urine L-FABP appeared to to be a more sensitive predictor of AKI than 
serum creatinine, and differentiated patients with septic shock from those with severe sepsis 
[Nakamura, Sugaya, Koide 2009]. Urine L-FABP can predict AKI in pediatric 
cardiopulmonary bypass surgery with AUC of 0.81 at 4-hours post-surgery [Portilla, Dent, 
Sugaya et al. 2008]. Although urine L-FABP is an early, accurate biomarker of AKI, it 
appears later than NGAL [Moore E, Bellomo R, Nichol. 2010]. 
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People who have risk factors of AKI (eg, past history of AKI, CKD or diabetes mellitus) 
should be treated as carefully as possible [Lamaire, Adam, Becker et al. 1999]. The best 
method for preventing contrast media induced AKI is to avoid use of contrast media. If 
contrast media must be used, the most effective prevention is to avoid volume depletion and 
to assure adequate volume [Davidson, Hlatky, Morris et al. 1989, Cigarroa, Lange, Williams 
et al. 1989]. The effect of administration of N-acetylcysteine (NAC) is controversial [Fishbane 
2008] and there is no convincing evidence of benefits in periprocedual blood purification 
[Frank H, Werner D, Lorusso V et al. (2003), Vogt B, Ferrari P, Schonholzer C et al. (2001)]. 
Since renal autoregulatory capacity maintains renal blood flow, several vasopressors 
including dopamine, norepinephrine, vasopressin and terlipressin, have been used or tested 
for prevention of renal ischemia. There is no clear convincing evidence on the beneficial 
effects of these agents for treating AKI [Rudnik MR, Kesselheim A, Goldfarb S (2006)]. 
There are currently no specific pharmacological interventions for patients with established 
AKI but renal replacement therapy (RRT) is a key component of supportive care. AKI 
associated with cancer shows substantial morbidity and mortality. Among critically ill 
cancer patients, 12-49% experience AKI and 9-32% need RRT [Lanore JJ, Brunet F, Pchard st 
al. 1991, Benoit, Hoste, Depuydt et al. 2005, Azoulay, Recher, Alberti C et al. 1999, Azoulay, 
Moreau, Alberti et al. 2000, Darmon, Thiery, Ciroldi et al. 2005]. These figures are much 
higher than those for critically ill patients without cancer. Most of the studies on AKI in 
cancer patients focus on patients with hematological malignancies whose mortality is over 
80% when RRT is necessary [Zager, O’Quigley, Zager et al. 1989]. Studies focusing on AKI 
in renal tumor patients have not been reported. In a cohort study, the benefits of early organ 
support including RRT was shown in the patients with non-hematological cancers 
associated with AKI [Darmon, Thiery, Ciroldi et al. 2007]. AKI, which has multiple causes 
and shows higher mortality in cancer patients, allows physicians to perform reluctant RRT, 
but there are no adequate treatment guidelines for AKI in patients with malignancies. 
5.1 Dosage in renal replacement therapy (RRT) 
The effectiveness of RRT can be adjusted by the rate of solute clearance (duration of the 
session) and/or the frequency of RRT sessions. The assessment of RRT dose is traditionally 
performed by single-pooled Kt/V urea. This refers to fractional clearance of urea (K), which 
takes into consideration therapy duration (t) and volume of distribution of urea in the body 
(V). In contrast to end stage kidney disease (ESKD) patients, critically ill patients with AKI 
have an unstable metabolic status (eg. hypercatabolism and fluid expansion). When 
continuous RRT (CRRT) is performed, ultrafiltration volume acts as a surrogate for 
clearance, based on with sieving coefficient of most small solutes such as urea. Therefore, 
application of Kt/V urea in critically ill patients has its limitations [Schiffl, Lang, Fischer 
2002]. The RRT adequacy is more complex than small-solute removal. Fluid overload has 
been independently associated with increased mortality of AKI [Payen, de Pont, Sakr et al. 
2008, Bouchard J, Soroko S Chertow G et al. 2009]. 
5.2 Intensity of RRT and outcome 
Renal replacement therapy (RRT) is usually performed in critically ill patients by 
intermittent hemodialysis or continuous RRT (CRRT). CRRT is performed together with 
hemofiltration, dialysis or a combination of them. The efficacy of CRRT for critically  
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ill patients is not superior to that of intermittent hemodialysis [Himmelfarb 2007]. Studies 
on the dose of intermittent hemodialysis (IHD) or CRRT and their outcomes have shown 
conflicting results although some clinical trials suggested an improvement in survival 
with higher doses of RRT [Ronco, Bellomo, Homel et al. 2000, Palvesky, Zhang, O’Connor 
et al. 2008, Bellomo, Cass, Cole et al. 2009, Tolwani, Cruz, Fumagalli et al. 2008, Boumann, 
Oudemans-Van Straaten, Tijssen et al. 2002, Saudan, Niederberger, Seigneux et al.  
2006]. One of the reasons for this phenomenon is that there is considered to be an 
inflection point separating the dose-response portion and dose-independent portion 
between RRT dose and survival. Recent multicenter randomized trials showed that higher 
intensity of CRRT or IHD did not reduce mortality of critically ill patients with AKI 
[Palvesky, Zhang, O’Connor et al. 2008, Bellomo, Cass, Cole et al]. If a critically ill patient 
with AKI is given RRT, the mortality is expected to be over 90%. Under-dialysis for 
critically ill patients with AKI results in higher mortality because of uremic complications. 
The correct dose is around the infection point, at which the RRT dose is not too small but 
not excessive. 
5.3 Recommendation of RRT for critically ill patients with AKI 
The balance of current evidence suggests that CRRT should be performed with an effluent 
flow rate higher than 20-25ml/kg/h in hemodynamicaly unstable patients with AKI. 
Alternative-day IHD is acceptable in more stable patients and minimum single pool Kt/V 
urea of 1.2-1.4 is recommended [Schiffl 2010]. Clinicians should check whether patients 
actually receive the current optimal doses of RRT. Higher doses and more intensive therapy 
can be considered if patients become extremely hypercatabolic or have a volume overload. 
6. Conclusion 
Although a large number of studies have been performed on AKI, little is known about its 
pathophysiology, appropriate diagnosis or treatment. It is hoped that further studies will 
improve the prognosis of patients with AKI. It appears that suitable treatments should be 
selected for AKI especially in patients with malignancies. 
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